BofA reiterates LyondellBasell stock Underperform rating at $68

BofA Securities kept an Underperform rating on LyondellBasell but raised its 2026 EBITDA estimate to $5.61B from $5.08B and maintained a $68 price target, citing a stronger margin outlook. The article also notes Q1 adjusted EPS of $0.49 versus $0.24 expected, though revenue missed at $7.2B versus $7.35B consensus. JPMorgan lifted its price target to $75 from $50 after domestic polyethylene prices settled higher, potentially adding about $2.25B to annualized EBITDA.

Analysis

The most interesting signal here is not the price-target dispersion itself, but the growing divergence in how the market is valuing commodity normalization versus idiosyncratic execution. LYB is starting to look less like a cyclicals-on-the-margins story and more like a balance-sheet/portfolio optionality story: asset divestitures plus better pricing in key poly streams can support near-term EBITDA even if end-demand remains mediocre. That tends to compress downside volatility in the stock, but it also caps upside because investors will demand proof that margin gains are durable rather than just a quarter or two of favorable spread conditions.

Second-order winners are likely upstream feedstock and logistics-linked names, not just direct peers. If North American polyethylene pricing is firming while Europe is being rationalized, the relative loser is the higher-cost global producer base that lacks the same export flexibility or asset rationalization runway; that argues for relative value shorts in weaker global chemical exposures versus LYB rather than outright index hedges. DOW is the most obvious comparator because any improvement in poly economics helps the whole complex, but LYB’s asset-sale/portfolio cleanup means it should outperform on free-cash-flow conversion even if absolute EBITDA revisions continue to migrate higher across the group.

The contrarian risk is that the market may be extrapolating a few months of better spreads into a multi-year earnings reset. If domestic pricing rolls over or global supply rebalances faster than expected, the current rerating can unwind quickly because chemicals multiples are still being anchored to mid-cycle EBITDA, not peak EBITDA. The key catalyst window is the next 1-2 quarters: if pricing holds through summer maintenance season, sentiment likely grinds higher; if not, the stock could give back a meaningful portion of the recent move despite the improved estimates.

Key Decisions for Investors

• Long LYB / short DOW for 1-3 months: prefer the cleaner capital-return and portfolio simplification story at LYB versus a more levered beta exposure to the same polyethylene improvement. Target 6-10% relative outperformance if spreads stay firm; stop if pricing data softens two consecutive weeks.
• Buy LYB call spreads into any 2-3% pullback over the next 2 weeks: structure upside to capture another estimate revision cycle while limiting premium decay if the move stalls. Best setup is a 3-4 month tenor, as the thesis needs one more earnings print to validate.
• Short a basket of higher-cost global chemical producers against LYB on a relative basis for 1-2 quarters: the market is underpricing the advantage of asset rationalization and export flexibility. Use a market-neutral structure to isolate margin normalization risk rather than directional equity beta.
• Take profits on any LYB strength above the current target-reset zone: chemicals often overshoot on estimate revisions, but once the sell-side converges, upside becomes multiple-limited. Reduce exposure if the stock rerates ahead of visible free-cash-flow conversion.
• Monitor DOW and other poly-sensitive names for follow-through only if domestic pricing remains sticky into the next pricing cycle; otherwise, fade broad sympathy bids as a lower-quality version of the LYB thesis.